estrone has been researched along with Menopause, Premature in 5 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Menopause, Premature: The premature cessation of menses (MENSTRUATION) when the last menstrual period occurs in a woman under the age of 40. It is due to the depletion of OVARIAN FOLLICLES. Premature MENOPAUSE can be caused by diseases; OVARIECTOMY; RADIATION; chemicals; and chromosomal abnormalities.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kapetanakis, E | 1 |
Dmowski, WP | 1 |
Auletta, F | 1 |
Scommegna, A | 1 |
Lillienberg, L | 1 |
Adlercreutz, H | 1 |
Svanborg, A | 1 |
Steingold, KA | 1 |
Matt, DW | 1 |
DeZiegler, D | 1 |
Sealey, JE | 1 |
Fratkin, M | 1 |
Reznikov, S | 1 |
Sherwin, BB | 2 |
Suranyi-Cadotte, BE | 1 |
Gelfand, MM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Mechanistic Examination of Continuous Cycle Oral Contractive Administration in Binge Eating[NCT04278755] | Phase 2 | 8 participants (Actual) | Interventional | 2020-09-24 | Terminated (stopped due to Halted prematurely due to COVID-19-related enrollment challenges.) | ||
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320] | Phase 2 | 23 participants (Actual) | Interventional | 2020-01-02 | Completed | ||
Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.[NCT00248989] | Phase 3 | 150 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Behavioral Inhibition/Behavioral Activation questionnaire will be used to assess behavioural inhibition (BI). The minimum score on the BI subscale is 7, maximum 28. Greater scores indicate greater BI. Change is defined as the average change in BI from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | 1.43 |
"Binge eating will be measured using the 8-item binge eating subscale of the Eating Pathology Symptoms Inventory (EPSI), which measures features of binge eating (e.g., consumption of large quantities of food, mindless eating) on a 5-point Likert scale from never to very often. The EPSI scale is designed to assess behavior over the past 28 days. Items are summed for a scale score ranging from 0-32. Higher scores indicate more frequent experiences with binge eating behavior. Change is defined as the average change in the binge eating scale score from pre-intervention to intervention." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | -6.60 |
The Monetary Choice Questionnaire will be used to measure delay discounting. Participants will be asked to make a series of hypothetical choices between small, sooner (impulsive) vs. larger, later (self controlled) hypothetical monetary outcomes. k is a hyperbolic function with larger k values indicating more valuation of a larger delayed reward and smaller values indicating preference for more immediate, smaller rewards (more impulsivity). k can range from 0 to .25 with scores of .25 indicating complete valuation of the immediate reward and 0 indicating complete valuation of the larger, delayed reward. Change is defined as the average change in k from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | k value (Mean) |
---|---|
Continuous OC | .01 |
"Nucleus Accumbens (NAcc) reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) |
---|---|
Continuous OC | .0423 |
"Prefrontal cortex reactivity to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) |
---|---|
Continuous OC | .01 |
Sensitivity to Punishment/Sensitivity to Reward Questionnaire will be used to measure reward sensitivity. The reward sensitivity subscale will be used, which is rated on a true/false scale with scores ranging 0-24. Higher scores indicate more sensitivity to reward. Change is defined as the average change in reward sensitivity from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | score on a scale (Mean) |
---|---|
Continuous OC | 1.60 |
Binge eating frequency is based on a weekly diary of self-reported binge eating frequency. Participants were asked how many times during the past week they had a binge eating episode. Scores can range from 0 to infinity as frequency is self-reported as the number of binge eating episodes in the previous week. Higher scores indicate more episodes of binge eating. Change is defined as the average change in self-reported binge eating frequency from pre-intervention to intervention. (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | episodes/week (Mean) |
---|---|
Continuous OC | -0.43 |
"Dorsal striatum reactivity (defined as caudate signal intensity and putamen signal intensity) to reward during the Monetary Incentive Delay (MIDT) task compared pre and post treatment. During MIDT task, participants respond to win trials by pressing a button on a button box in the MRI as quickly as possible when they see a target. Reactivity is measured by examining participant's change in blood-oxygen-level dependent (BOLD) (i.e., measurement of oxygen level that is carried to neurons by red blood cells since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen) in response to a stimulus of interest (win trials) versus non-stimulus (non-win trials). Percent signal change in BOLD activation between monetary reward versus non-reward is the outcome of interest. Percent signal change is then compared pre- and post-treatment." (NCT04278755)
Timeframe: Pre-intervention (week 1) to intervention endpoint (week 12)
Intervention | percentage signal change (Mean) | |
---|---|---|
Caudate | Putamen | |
Continuous OC | -.012 | .02 |
"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.18 |
Hormone Insensitive Women (HS-) | 0.03 |
"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.47 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.35 |
Hormone Insensitive Women (HS-) | 0.11 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Mean) |
---|---|
Hormone Sensitive Women (HS+) | -0.13 |
Hormone Insensitive Women (HS-) | 0.49 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.57 |
Hormone Insensitive Women (HS-) | -0.08 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | -0.009866667 | -0.086876444 |
Hormone Sensitive Women (HS+) | 0.005316917 | -0.047401917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0077258 | -0.049988 |
Hormone Sensitive Women (HS+) | -0.043943333 | 0.059099917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0691907 | -0.072512 |
Hormone Sensitive Women (HS+) | -0.028451818 | 0.031632727 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0383029 | -0.021029 |
Hormone Sensitive Women (HS+) | -0.001223462 | 0.048155385 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.037334 | -0.15643 |
Hormone Sensitive Women (HS+) | -0.04544 | 0.022654 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.061407 | 0.0058011 |
Hormone Sensitive Women (HS+) | -0.069919077 | 0.045146154 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.052685333 | -0.006394444 |
Hormone Sensitive Women (HS+) | 0.044384167 | -0.005181667 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.002542222 | -0.080736333 |
Hormone Sensitive Women (HS+) | -0.007560692 | 0.036225385 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0213 | 0.00111 |
Hormone Sensitive Women (HS+) | 0.0247 | -0.0192 |
"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Number of subtraction responses (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 129.20 | 54.90 |
Hormone Sensitive Women (HS+) | 103.08 | 34.62 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0533 | 0.00804 |
Hormone Sensitive Women (HS+) | 0.0174 | -0.0114 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | attention bias in milliseconds (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 36.92 | -42.35 |
Hormone Sensitive Women (HS+) | -0.57 | -9.04 |
3 trials available for estrone and Menopause, Premature
Article | Year |
---|---|
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est | 1991 |
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est | 1991 |
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est | 1991 |
Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Estradiol; Estrogen Replacement Therapy; Est | 1991 |
Up-regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopausal women.
Topics: Affect; Blood Platelets; Carrier Proteins; Estradiol; Estrogen Replacement Therapy; Estrone; Female; | 1990 |
Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause.
Topics: Adult; Androgens; Appetite; Castration; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1985 |
2 other studies available for estrone and Menopause, Premature
Article | Year |
---|---|
Endocrine and clinical effects of estradiol and testosterone pellets used in long-term replacement therapy.
Topics: Adult; Drug Implants; Drug Therapy, Combination; Estradiol; Estrogens; Estrone; Female; Follicle Sti | 1982 |
Effect of a sequential oestrogen-progestin therapy on the plasma level of oestrogens and lipids in post-menopausal women.
Topics: Aged; Castration; Cholesterol; Drug Therapy, Combination; Estradiol; Estrogens; Estrone; Ethinyl Est | 1979 |